References
- Anwar A, Dehn D, Siegel D, et al (2003). Interaction of human NAD (P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem, 278, 10368-73. https://doi.org/10.1074/jbc.M211981200
- Asher G, Lotem J, Cohen B, et al (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA, 98, 1188-93. https://doi.org/10.1073/pnas.98.3.1188
- Chao C, Zhang ZF, Berthiller J, et al (2006). NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87. https://doi.org/10.1158/1055-9965.EPI-05-0899
- Chen H, Lum A, Seifried A, et al (1999). Association of the NAD (P) H: Quinone oxidoreductase 609CT polymorphism with a decreased lung cancer risk. Cancer Res, 59, 3045-8.
- Chen J, Lin Y, Zhang R, et al (2012). Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res, 43, 58-66. https://doi.org/10.1016/j.arcmed.2012.01.005
- Guha N, Chang JS, Chokkalingam AP, et al (2008). NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol, 168, 1221-32.
- Hamajima N, Matsuo K, Iwata H, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
- Haruya K, Nobuyuki H, Akiko T, et al (2003). Triplex polymerase chain reactions with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 polymorphisms: a convenient genotyping method.
- Hou L, Chatterjee N, Huang W, et al (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use and risk for colorectal adenoma. Carcinogenesis, 26, 1122-8. https://doi.org/10.1093/carcin/bgi054
- Kolesar JM, Dahlberg SE, Marsh S, et al (2011). The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep, 25, 1765-72.
- Larson RA, Wang X, Banerjee M, et al (1999). Prevalence of the inactivating 609C to T polymorphism in the NAD(P) H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-7.
- Lewis SJ, Cherry NM, Niven RM, et al (2001). Polymorphisms in theNAD( P)H: quinine oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-83. https://doi.org/10.1016/S0169-5002(01)00243-4
- Mei-Miao C, Ying-Ju K, Ann-Ping T, et al (2009). Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol Histopathol, 24, 1223-32.
- Menashe I, Figueroa JD, Garcia-Closas M, et al (2012). Largescale pathwaybased analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One, 7, 29396. https://doi.org/10.1371/journal.pone.0029396
- Nebert DW, Roe AL, Vandale SE, et al (2002). NAD (P) H:quinine oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70. https://doi.org/10.1097/00125817-200203000-00003
- Ren JJ, OuYang XH, Su XL (2006). NAD (P)H:quinone oxidoreductase gene polymorphism association with gastric carcinoma. Zhong Hua Zhong liu Fang Zhi Za Zhi (in Chinese), 22, 1686-8.
- Ross D (2004). NQO1. Atlas genet cytogenet oncol haematol. URL : http://AtlasGeneticsOncology.org/Genes/NQO1ID375.html.
- Rosvold EA, McGlynn KA, Lustbader ED, et al (1995). Identification of an NAD (P) H: quinone oxidor - eductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199. https://doi.org/10.1097/00008571-199508000-00003
- Sarmanova J, Susova S, Gut I, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Gen, 12, 848-54. https://doi.org/10.1038/sj.ejhg.5201249
- Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9. https://doi.org/10.1097/00008571-199706000-00008
- Siegel D, Anwar A, Winski SL, et al (2001). Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P)H:quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8. https://doi.org/10.1124/mol.59.2.263
- Su XL, Yan MR, Yang L, et al (2012). NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Chin J Cancer Res, 24, 317-322. https://doi.org/10.1007/s11670-012-0270-0
- Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75. https://doi.org/10.1038/bjc.1997.11
- Wiemels JL, Pagnamenta A, Taylor GM, et al (1999). United Kingdom Childhood Cancer Study Investigators. A lack of a functional NAD(P)H: quinine oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res, 59, 4095-9.
- Xu LL, Wain JC, Miller DP, et al (2001). The NAD (P) H: quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer Differential Susceptibility Based on Smoking Behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.
- Yuan W, Xu L, Chen W, et al (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 467-72. https://doi.org/10.1007/s10549-010-0966-0
Cited by
- Association Between Polymorphisms of Metabolic Enzyme Genes and Chromosomal Damage in Benzene-Exposed Workers in China vol.59, pp.11, 2017, https://doi.org/10.1097/JOM.0000000000001148